|
Each tablet contains:
Composition:
Nevirapine......................................................................
200 mg
Lamivudine
....................................................................150
mg
Stavudine.........................................................................
30 mg
Indications:
Progressive or advanced HIV infection, in combination
with atleast 2 other antiretroviral drugs.
Description:
Nevirapine binds directly to reverse transcriptase (RT)
and blocks the RNA-dependent and DNA-dependent DNA
polymerase activities by causing a disruption of the
enzyme's catalytic site. The activity of nevirapine does
not compete with template or nucleoside triphosphates.
Lamivudine is a cytosine analog. After lamivudine
is triphosphorylated, it inhibits HIV reverse
transcription via viral DNA chain termination and
inhibits RNA- and DNA-dependent DNA polymerase
activities of reverse transcriptase.
The monophosphate form of lamivudine is incorporated
into the viral DNA by hepatitis B virus polymerase,
resulting in DNA chain termination.
Stavudine is an
analog of
thymidine. It
is phosphorylated by cellular
kinases into
active triphosphate. Stavudine triphosphate inhibits the
HIV
reverse transcriptase
by competing with natural substrate, thymidine
triphosphate. It also causes termination of
DNA synthesis
by incorporating into it.
Simultaneous use of
AZT is not
recommended, as it can inhibit the intracellular
phosphorylation
of stavudine. Other anti-HIV drugs do not possess this
property.
Dosage :
Adult: 200mg once daily for first 14 days and if no rash
appears increase to 200mg twice daily.
Children: 2 months-8 years: 4mg/kg once daily for first
14 days and then if no rash 7mg/kg twice daily
(maximum:400mg daily) 8-16 years (below 50kg): 4mg once
daily for 1st 14 days and then if no rash, 4mg twice
daily (maximum: 400mg daily) Over 50kg: Adult dose.
Presentations:
MRP
Retailer Stockist
30 tablets
615.50
492.40
443.16
60
tablets
629.50
503.60
453.24
| 
